

SCHEDULE 13G

Amendment No. 1  
Cytotherapeutics Incorporated  
common stock  
Cusip # 232923102  
Filing Fee: No

Cusip # 232923102  
Item 1: Reporting Person - FMR Corp. - (Tax ID: 04-2507163)  
Item 4: Commonwealth of Massachusetts  
Item 5: 14,900  
Item 6: None  
Item 7: 14,900  
Item 8: None  
Item 9: 14,900  
Item 11: 0.14%  
Item 12: HC

Cusip # 232923102  
Item 1: Reporting Person - Edward C. Johnson 3d - (Tax ID: ###-##-####)  
Item 4: United States of America  
Item 5: None  
Item 6: None  
Item 7: 14,900  
Item 8: None  
Item 9: 14,900  
Item 11: 0.14%  
Item 12: IN

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Item 1(a). Name of Issuer:  
Cytotherapeutics Incorporated

Item 1(b). Name of Issuer's Principal Executive Offices:  
2 Richmond Square  
Providence, RI 02906

Item 2(a). Name of Person Filing:  
FMR Corp.

Item 2(b). Address or Principal Business Office or, if None, Residence:  
82 Devonshire Street, Boston, Massachusetts 02109

Item 2(c). Citizenship:  
Not applicable

Item 2(d). Title of Class of Securities:  
Common Stock

Item 2(e). CUSIP Number:  
232923102

Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, FMR Corp., is a parent holding company in accordance with Section 240.13d-1(b)(ii)(G). (Note: See Item 7).

Item 4. Ownership

(a) Amount Beneficially Owned:  
14,900

(b) Percent of Class:  
0.14%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote:  
14,900

(ii) shared power to vote or to direct the vote:  
None

(iii) sole power to dispose or to direct the disposition of:  
14,900

(iv) shared power to dispose or to direct the disposition of:  
None

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X).

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

See attached Exhibit(s) A and B.

Item 8. Identification and Classification of Members of the Group.

Not applicable, see attached Exhibit A.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Inasmuch as the reporting persons are no longer the beneficial owners of more than five percent of the number of shares outstanding, the reporting persons have no further reporting obligation under section 13(d) of the Securities and Exchange Commission thereunder, and the reporting persons have no obligation to amend this Statement if any material change occurs in the facts set forth herein.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 13G in connection with FMR Corp's beneficial ownership of the common stock of Cytotherapeutics Incorporated at December 31, 1994 is true, complete and correct.

February 13, 1995

Date

/s/Arthur S. Loring

Signature

Arthur S. Loring, Vice  
President  
Name/Title

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Pursuant to the instructions in Item 7 of Schedule 13G, Fidelity Management Trust Company, 82 Devonshire Street, Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR Corp. and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, is the beneficial owner of 14,900 shares or 0.14% of the common stock outstanding of the company as a result of its serving as investment manager of the institutional account(s).

Edward C. Johnson 3d and FMR Corp., through its control of Fidelity Management Trust Company, has sole voting and dispositive power over 14,900 shares of common stock owned by the institutional account(s) as reported above.

Edward C. Johnson 3d and Abigail P. Johnson each own 24.9% of the outstanding voting common stock of FMR Corp. Mr. Johnson 3d is Chairman of FMR Corp. Various Johnson family members and trusts for the benefit of Johnson family members own FMR Corp. voting common stock. These Johnson family members, through their ownership of voting common stock and the execution of a family shareholders' voting agreement, form a controlling group with respect to FMR Corp.

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

RULE 13d-1(f)(1) AGREEMENT

The undersigned persons, on February 13, 1995, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the common stock of Cytotherapeutics Incorporated at December 31, 1994.

FMR Corp.

By /s/Arthur S. Loring

Arthur S. Loring

Vice President - Legal

Edward C. Johnson 3d

By /s/Arthur S. Loring

Arthur S. Loring

Under Power of Attorney dated

5/17/89

On File with Schedule 13G for

Airborne Freight Corp. 9/10/91

Fidelity Management & Research Company

By /s/Arthur S. Loring

Arthur S. Loring

Sr. V.P. and General Counsel